
During the last decade immunotherapy for human cancer has been investigated in a remarkable number of clinical trials. To date, no significant advantage has been found compared to other forms of cancer treatment. However, promising results of recent trials require further confirmation. Knowledge of immunotherapeutic modalities, dosages and timing for an effective treatment, as well as criteria of the patients' condition remain unsolved.

